489 related articles for article (PubMed ID: 33329566)
1. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.
Zuazo M; Arasanz H; Bocanegra A; Fernandez G; Chocarro L; Vera R; Kochan G; Escors D
Front Immunol; 2020; 11():586907. PubMed ID: 33329566
[TBL] [Abstract][Full Text] [Related]
2. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
3. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.
Escors D; Bocanegra A; Chocarro L; Blanco E; Piñeiro-Hermida S; Garnica M; Fernandez-Rubio L; Vera R; Arasanz H; Kochan G
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362027
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
5. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Zuazo M; Arasanz H; Fernández-Hinojal G; García-Granda MJ; Gato M; Bocanegra A; Martínez M; Hernández B; Teijeira L; Morilla I; Lecumberri MJ; Fernández de Lascoiti A; Vera R; Kochan G; Escors D
EMBO Mol Med; 2019 Jul; 11(7):e10293. PubMed ID: 31273938
[TBL] [Abstract][Full Text] [Related]
6. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade augments humoral immunity through ICOS-mediated CD4
Zhang M; Xia L; Yang Y; Liu S; Ji P; Wang S; Chen Y; Liu Z; Zhang Y; Lu S; Wang Y
Int Immunopharmacol; 2019 Jan; 66():127-138. PubMed ID: 30448635
[TBL] [Abstract][Full Text] [Related]
8. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
14. Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy.
Sckisel GD; Mirsoian A; Minnar CM; Crittenden M; Curti B; Chen JQ; Blazar BR; Borowsky AD; Monjazeb AM; Murphy WJ
J Immunother Cancer; 2017; 5():33. PubMed ID: 28428882
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.
Gitto S; Natalini A; Antonangeli F; Di Rosa F
Front Immunol; 2021; 12():755304. PubMed ID: 34867987
[TBL] [Abstract][Full Text] [Related]
16. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
17. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
18. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
20. Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapy.
Zuazo M; Arasanz H; Bocanegra A; Chocarro L; Vera R; Escors D; Kagamu H; Kochan G
EMBO Mol Med; 2020 Sep; 12(9):e12706. PubMed ID: 32648370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
